WallStreetZenWallStreetZen

NASDAQ: CYTH
Cyclo Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for CYTH

Based on 2 analysts offering 12 month price targets for Cyclo Therapeutics Inc.
Min Forecast
$2.60+92.59%
Avg Forecast
$2.80+107.41%
Max Forecast
$3.00+122.22%

Should I buy or sell CYTH stock?

Based on 2 analysts offering ratings for Cyclo Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CYTH stock forecasts and price targets.

CYTH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-01
lockedlocked$00.00+00.00%2024-04-22

1 of 1

Forecast return on equity

Is CYTH forecast to generate an efficient return?

Forecast return on assets

Is CYTH forecast to generate an efficient return on assets?

CYTH revenue forecast

What is CYTH's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$1.7M+54.47%
Avg 2 year Forecast
$1.8M+58.91%
Avg 3 year Forecast
$1.9M+64.23%
CYTH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CYTH revenue growth forecast

How is CYTH forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
17.95%
Industry
8.1%
Market
10.44%
CYTH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CYTH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CYTH vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
CYTH$1.35$2.80+107.41%Buy
BGXX$0.21N/AN/A
DRRX$1.30$5.00+284.62%Buy
IXHL$2.78N/AN/A
QLI$0.87N/AN/A

Cyclo Therapeutics Stock Forecast FAQ

Is Cyclo Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CYTH) stock is to Buy CYTH stock.

Out of 2 analysts, 0 (0%) are recommending CYTH as a Strong Buy, 2 (100%) are recommending CYTH as a Buy, 0 (0%) are recommending CYTH as a Hold, 0 (0%) are recommending CYTH as a Sell, and 0 (0%) are recommending CYTH as a Strong Sell.

If you're new to stock investing, here's how to buy Cyclo Therapeutics stock.

What is CYTH's revenue growth forecast for 2024-2026?

(NASDAQ: CYTH) Cyclo Therapeutics's forecast annual revenue growth rate of 17.95% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.1%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.44%.

Cyclo Therapeutics's revenue in 2024 is $1,126,444.On average, 1 Wall Street analysts forecast CYTH's revenue for 2024 to be $49,791,388, with the lowest CYTH revenue forecast at $49,791,388, and the highest CYTH revenue forecast at $49,791,388. On average, 1 Wall Street analysts forecast CYTH's revenue for 2025 to be $51,222,175, with the lowest CYTH revenue forecast at $51,222,175, and the highest CYTH revenue forecast at $51,222,175.

In 2026, CYTH is forecast to generate $52,939,119 in revenue, with the lowest revenue forecast at $52,939,119 and the highest revenue forecast at $52,939,119.

What is CYTH's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CYTH) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of N/A.

What is CYTH's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CYTH price target, the average CYTH price target is $2.80, with the highest CYTH stock price forecast at $3.00 and the lowest CYTH stock price forecast at $2.60.

On average, Wall Street analysts predict that Cyclo Therapeutics's share price could reach $2.80 by May 1, 2025. The average Cyclo Therapeutics stock price prediction forecasts a potential upside of 107.41% from the current CYTH share price of $1.35.

What is CYTH's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CYTH) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.